The Regulation of INK4/ARF in Cancer and Aging  by Kim, William Y. & Sharpless, Norman E.
Leading Edge
ReviewThe Regulation of INK4/ARF  
in Cancer and Aging
William Y. Kim1 and Norman E. Sharpless1,*
1Departments of Medicine and Genetics, The University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
*Contact: nes@med.unc.edu
DOI 10.1016/j.cell.2006.10.003
Loss of the INK4a/ARF/INK4b locus on chromosome 9p21 is among the most frequent 
cytogenetic events in human cancer. The products of the locus—p15INK4b, p16INK4a, and 
ARF—play widespread and independent roles in tumor suppression. Recent data also 
suggest that expression of p16INK4a induces an age-dependent decrease in the proliferative 
capacity of certain tissue-specific stem cells and unipotent progenitors. Here, we discuss 
the regulation and role of p16INK4a, ARF, and p15INK4b in cancer and aging.Regulated cellular proliferation is required for mamma-
lian homeostasis, but uncontrolled proliferation is the 
hallmark of cancer. Therefore, an important question in 
cancer biology is how a tumor suppressor protein dis-
tinguishes malignant from physiological growth? This is 
no mean feat. Physiologic growth can have many of the 
properties associated with the worst malignancies: it 
can be rapid, disordered, unexpected, and invasive (for 
example, an inflammatory response to a wound). Cells 
harboring oncogenic mutations in vivo often respond by 
activating expression of the INK4a/ARF/INK4b locus, 
which encodes critical tumor suppressor proteins. This 
indicates that cells understand at a very early stage of 
transformation that something has gone awry. Under-
standing in molecular terms what regulates the INK4a/
ARF/INK4b locus should help to elucidate the properties 
a would-be cancer cell recognizes as malignant. This 
question has taken on additional importance given recent 
evidence that at least one product of the locus, p16INK4a, 
also contributes to the decline in replicative potential of 
self-renewing cells during aging. These observations 
suggest the provocative but unproven notion that mam-
malian aging results in part from the beneficial efforts 
of tumor suppressor proteins to interdict cancer. In this 
review, we discuss the regulation and function of INK4a/
ARF/INK4b with regard to cancer and aging.
The INK4 Family and ARF
The INK4a/ARF/INK4b locus (also known as CDKN2a 
and CDKN2b) is deleted in a wide spectrum of tumors 
including melanoma, pancreatic adenocarcinoma, gliob-
lastoma, certain leukemias, non-small cell lung cancer, 
and bladder carcinoma. In a small 35 kb stretch of the 
human genome, the locus encodes three related genes 
(ARF [also known as p19ARF and p14ARF], p15INK4b, and 
p16INK4a) that encode distinct tumor suppressor proteins 
(reviewed in Sherr, 2000). Whereas p15INK4b has its own 
open reading frame that is physically distinct, p16INK4a 
and ARF have different first exons that are spliced to a common second and third exon. Although exons 2 and 3 
are shared by p16INK4a and ARF, the proteins are encoded 
in alternative reading frames. As a consequence p16INK4a 
and ARF are not isoforms and do not share any amino 
acid homology (Figure 1).
The INK4 class of cell-cycle inhibitors p15INK4b, p16INK4a, 
p18INK4c, and p19INKd (the latter not to be confused with 
p19ARF) are homologous inhibitors of the cyclin-dependent 
kinases, CDK4 and CDK6, which promote proliferation. In 
particular, p15INK4b and p16INK4a are 85% similar at the amino 
acid level and little biochemical distinction has been made 
between these proteins (reviewed in Sharpless, 2005). The 
binding of the INK4 proteins to CDK4 and CDK6 induces 
an allosteric change that abrogates the binding of these 
kinases to D-type cyclins, inhibiting CDK4/6-mediated 
phosphorylation of retinoblastoma (Rb) family members. 
Thus, expression of p15INK4b or p16INK4a maintains Rb-family 
proteins in a hypophosphorylated state, which promotes 
binding E2F to effect a G1 cell-cycle arrest.
Figure 1. The INK4a/ARF/INK4b Locus
The INK4a/ARF/INK4b locus encodes three genes within 35 kilobas-
es: ARF, p15INK4b, and p16INK4a. Members of the INK4 family of cyclin-
dependent kinase inhibitors bind to and inactivate CDK4/6. ARF in-
hibits MDM2, resulting in p53 stabilization. RDINK/ARF indicates a newly 
discovered origin of replication 5′ to p15INK4b that participates in the 
transcriptional silencing of the INK4a/ARF/INK4b locus.Cell 127, October 20, 2006 ©2006 Elsevier Inc. 265
The tumor suppressor activity of ARF is largely 
ascribed to its ability to regulate p53 in response to 
aberrant growth or oncogenic stresses such as c-MYC 
activation (discussed below). ARF binds to and inacti-
vates the MDM2 protein, and MDM2 in turn negatively 
regulates p53. One mechanism that has been proposed 
to explain how MDM2 regulates p53 is that it acts as 
an E3 ubiquitin ligase to target p53 for proteasomal 
degradation. Although strong biochemical and genetic 
evidence link ARF and p53 in tumor suppression, sev-
eral p53-independent functions of ARF have also been 
reported. For example, Arf expression is required to 
induce vascular regression in the developing eye, which 
does not appear to require p53 (McKeller et al., 2002), 
and overexpression of Arf induces a cell-cycle arrest in 
murine embryo fibroblasts (MEFs) lacking p53 (Weber et 
al., 2000). Moreover, ARF has been reported to interact 
with multiple proteins other than MDM2, including E2F-1, 
MDMX, HIF-1α, topoisomerase I, MYC, and nucleophos-
min (NPM).
Arguably, the best characterized of these interac-
tions is between ARF and NPM (reviewed in Lindstrom 
and Zhang, 2006). NPM, also known as B23, is a pro-
tein that shuttles between the nucleolus and cytoplasm 
and is involved in several cellular processes including 
ribosome processing and centrosome duplication. The 
ARF-NPM interaction modulates ARF protein stability 
as suggested by the finding of reduced levels in cells 
lacking NPM. Additionally, it appears that this interac-
tion sequesters ARF in the nucleolus thus preventing it 
from binding MDM2. Specific point mutations of the C 
terminus of NPM are noted in ?30% of cases of primary 
adult acute myelogenous leukemia (AML) (Colombo et 
al., 2006; Falini et al., 2005). These mutant forms of NPM 
appear constitutively localized to the cytoplasm but 
retain the ability to bind ARF. Therefore, these mutations 
are believed to compromise the ARF-p53 pathway both 
by decreasing ARF’s protein stability and by mislocal-
izing ARF to the cytoplasm where it is unable to inac-
tivate MDM2 (Colombo et al., 2006; Falini et al., 2005). 
Although a compelling hypothesis, it is worth noting that 
NPM functions in many critical cellular processes related 
to growth and proliferation and therefore the “true” can-
cer-promoting activities of mutant NPM have not been 
fully determined.
The unusual genomic arrangement of the INK4a/ARF/
INK4b locus is assuredly a weakness in our anti-cancer 
defenses, as it renders three crucial regulators of the 
RB and p53 tumor suppressor pathways vulnerable to 
a single, relatively small deletion. This observation can 
be used to draw one of two opposite conclusions: either 
tumor formation provides no evolutionary selection pres-
sure (and the overlapping INK4a/ARF/INK4b locus is 
not selected against) or tumorigenesis provides such a 
strong pressure that an entire suite of tumor suppressor 
genes has been selected for at the INK4a/ARF/INK4b 
locus to prevent cancer. The finding that polymorphisms 
of the p15INK4b/p16INK4a homolog of Xiphophorus (sword-266 Cell 127, October 20, 2006 ©2006 Elsevier Inc.tail fish) segregate with melanoma susceptibility (Nairn 
et al., 1996) in this species suggests that INK4 proteins 
have played such a role in tumor suppression for more 
than 350 million years. In mammals and birds, therefore, 
the evolutionarily older, INK4-based system appears to 
have been further improved by the more recent addi-
tion of an ARF-based anti-cancer response. Implicit in 
the latter interpretation, however, is the notion that the 
physical proximity and shared sequences of the locus 
allow p16INK4a and ARF, and possibly p15INK4b as well, to 
sense and coordinately respond to common stimuli in 
nascent tumor cells. Evidence described in this review 
suggests that this is in fact the case—the response of 
the INK4a/ARF/INK4b locus efficiently prevents cancers 
that would result from the daily onslaught of oncogenic 
mutations suffered by long-lived mammals. Before turn-
ing to the crucial question of the in vivo regulation of the 
locus, we will review some of the evidence supporting 
this role for INK4a/ARF/INK4b products in the suppres-
sion of cancer and promotion of aging.
Role in Cancer and Aging
Cancer
As human cancers frequently harbor homozygous 
deletions of the INK4a/ARF/INK4b locus that abrogate 
expression of all three proteins, significant debate has 
focused on which member or members of the locus rep-
resents the principal tumor suppressor activity located 
at human chromosome 9p21. Knockout studies of mice 
specifically deficient for Arf, p15INK4b, or p16INK4a have 
revealed that all three strains are more prone to spon-
taneous cancers than wild-type littermates, but that 
each of these single knockouts appears significantly 
less tumor prone than animals lacking both p16INK4a 
and Arf (Latres et al., 2000; Sharpless et al., 2004). 
The finding of synergy between p16INK4a and Arf loss in 
murine cancers has been established in several tumor-
prone models including response to certain carcino-
gens, melanoma, glioblastoma, and pancreatic cancer 
(reviewed in Sharpless, 2005; see also Bardeesy et al., 
2006). Compound mutant animals lacking Arf/p15INK4b, 
p15INK4b/p16INK4a, or the entire Ink4a/Arf/Ink4b locus have 
not yet been reported.
Overexpression of the Ink4a/Arf/Ink4b locus in mice 
also supports its role in tumor suppression. Mice har-
boring an allele of the Ink4a/Arf/Ink4b locus on a bac-
terial artificial chromosome display modest overexpres-
sion of p16INK4a, p15INK4b, and Arf (the “super-Ink4/Arf” 
mice) (Matheu et al., 2004). These mice demonstrate a 
3-fold reduction in the incidence of spontaneous can-
cers, without an acceleration in the appearance of a 
few age-induced phenotypes such as kyphosis of the 
spine. Therefore, the authors suggest that an increase in 
tumor suppression can be achieved by increased Ink4a/
Arf/Ink4b activity without increased aging. As cancer 
is the principal cause of death of mice on this genetic 
background, however, one might argue that the marked 
tumor resistance of the super-Ink4/Arf mice would also 
be expected to increase longevity, yet the super-Ink4/Arf 
mice demonstrate a normal life span. Therefore, the fact 
that the super-Ink4a/Arf mice do not live longer suggests 
that increased Ink4a/Arf/Ink4b function and diminished 
tumor incidence may come at the cost of excess mor-
tality from nonmalignant causes related to aging. Thus, 
although these data confirm the potent tumor suppres-
sor activity of the Ink4a/Arf/Ink4b locus, we believe they 
also elegantly demonstrate a tradeoff between overly 
zealous tumor suppression and accelerated aging.
In human cancers, the goal of defining which protein(s) 
at the locus represent the relevant tumor suppressor 
has led to genetic searches of specific tumor types in an 
attempt to identify specific lesions that target one mem-
ber of the locus in the absence of mutation of the others. 
Such analyses make their strongest case for p16INK4a. For 
example, in a few malignancies where recurrent 9p21 
deletions have been most carefully mapped, the minimal 
region of deletion appears to center on exons 1α and 
2, but these analyses have not been comprehensive in 
most tumor types and will certainly soon be improved by 
ongoing high-resolution, genome-wide efforts at tumor 
genotyping. Specific somatic loss of p16INK4a, through 
point mutation or small deletion, has been reported in 
thousands of human cancers (Forbes et al., 2006). Simi-
larly, at least 56 distinct germline mutations targeting 
only p16INK4a, and sparing ARF and p15INK4b, have been 
described in unrelated kindreds that are cancer prone 
(Greenblatt et al., 2003). Finally, p16INK4a was one of the 
first genes noted to be silenced epigenetically in human 
cancers, and silencing through promoter methylation 
is well described at high frequency in numerous types 
of human cancers (Esteller et al., 2001). Indisputably, 
p16INK4a is an important suppressor of human cancer.
On the other hand, specific genetic lesions of p15INK4b, 
which do not also inactivate p16INK4a or ARF, are not well 
described. Specific epigenetic silencing by hypermeth-
ylation of the p15INK4b gene has been demonstrated in rare 
glial tumors and certain hematologic neoplasms includ-
ing leukemia and myelodysplasia (Esteller et al., 2001; 
Herman et al., 1996; Uchida et al., 1997). In myelodys-
plasia, p15INK4b hypermethylation has been reported in the 
absence of p16INK4a hypermethylation and in some of these 
cases the expression of p15INK4b can be reactivated in 
response to treatment with inhibitors of DNA methytrans-
ferase. Furthermore, because of their overlapping bio-
chemical function, co-deletion of p15INK4b with p16INK4a may 
be more oncogenic in certain tissues than loss of either 
alone. Such redundancy might explain why a few malig-
nancies (e.g., T cell acute lymphoblastic leukemia [ALL]) 
appear to show very high frequencies of homozygous 
deletion of 9p21 (targeting all three proteins) rather than 
specific inactivation of p16INK4a or ARF. Therefore, p15INK4b 
is probably an important suppressor of human cancers 
too, particularly in the hematopoietic lineages.
In murine cancer, the data show that the loss of Arf is 
potently oncogenic (Kamijo et al., 1997; Sharpless et al., 
2004), but selective inactivation of ARF, in the absence of a concomitant loss of p15INK4b and p16INK4a, has only 
been reported in a small number of cases of human 
cancer. For example, three distinct germline mutations 
that do not affect p16INK4a have been described in kin-
dreds with familial melanoma and astrocytoma (Hewitt 
et al., 2002; Randerson-Moor et al., 2001; Rizos et al., 
2001). Additionally, somatic ARF-specific mutations and 
promoter methylation have been reported in studies of 
colon cancer (Burri et al., 2001; Esteller et al., 2001), but 
such specific targeting events appear less common in 
human cancer than those affecting only p16INK4a. Some 
have argued that the relatively infrequent finding of 
lesions selectively targeting ARF indicates species dif-
ferences in the relative importance of p16INK4a and ARF 
in tumor suppression; that is, Arf is more important in 
mice, and p16INK4a more important in humans. We, how-
ever, suggest that these data can also be explained by 
a consideration of the biochemical nature of the ARF-
MDM2 interaction, which only requires a relatively small 
portion of the highly basic N terminus of ARF (Korga-
onkar et al., 2002). Therefore, missense mutations that 
disable ARF’s principal anticancer activity may be very 
improbable. Instead, we believe that the human and 
murine genetic data considered as a whole establish 
that the INK4a/ARF/INK4b locus encodes at least two 
(p16INK4a and ARF), and probably three, major human 
tumor suppressor proteins, although their relative and 
combinatorial importance in any given tumor type has 
not been fully resolved.
Aging
Recent evidence from several groups has suggested 
a role for the senescence machinery in mammalian 
aging. These experiments were motivated by the sem-
inal observation of Sherr and colleagues (Zindy et al., 
1997), later confirmed by several groups (Krishnamur-
thy et al., 2004; Melk et al., 2004; Nielsen et al., 1999), 
that the expression of p16INK4a increases markedly with 
aging in many tissues of rodents and humans. This find-
ing has now been extended to a large number of aging 
human tissues in health and disease and has led to the 
proposal that p16INK4a expression could be used as a 
biomarker of physiologic, as opposed to chronologic, 
age (Krishnamurthy et al., 2004). Moreover, as aging is 
characterized in part by a reduced ability of reservoirs 
of self-renewing tissue stem cells to regenerate lost or 
damaged cells, this observation has suggested the pos-
sibility that an age-induced increase in p16INK4a expres-
sion contributes to the decline of replicative potential of 
certain self-renewing compartments with aging.
Several lines of evidence suggest that p16INK4a expres-
sion participates in cell-autonomous aging in vivo. Much 
of this work to date has studied hematopoietic stem 
cells (HSCs), the best characterized adult stem cell. 
Surprisingly, murine HSC number does not necessarily 
decline with aging, and in some genetic strains, old mice 
actually harbor an increased number of HSCs based 
on immunophenotype (de Haan and Van Zant, 1999; 
Morrison et al., 1996). Transplantation studies from old Cell 127, October 20, 2006 ©2006 Elsevier Inc. 267
donors into young recipients, however, have established 
that a decline in HSC function does occur with aging, 
that this decline is cell autonomous, and that it is not 
rescued by ectopic telomerase expression (Allsopp et 
al., 2003; Morrison et al., 1996). Additionally, genotoxic 
stimuli such as ionizing radiation or busulfan exposure, 
which induce a durable compromise of HSC function, 
are known to potently induce p16INK4a expression in HSCs 
(Meng et al., 2003; Wang et al., 2006). Oxidative stress 
has also been suggested to induce an Ink4a/Arf-depend-
ent decline in HSC function (Ito et al., 2004, 2006). The 
Ink4a/Arf locus has been identified as a possible effec-
tor of a cell-autonomous decline in HSC function, as loss 
of both p16INK4a and Arf, but not Arf alone, increases the 
ability of HSCs to serially transplant and repopulate irra-
diated recipient mice (Stepanova and Sorrentino, 2005). 
In aggregate, these results demonstrate that HSCs carry 
the memory of prior aging, serial transplantation, and 
other age-promoting genotoxic exposures and suggest 
that p16INK4a expression is a mechanism whereby HSCs 
recognize that they are old.
These studies, however, do not directly address the 
question of whether p16INK4a plays a causal role in the age-
induced decline of replicative function in HSCs or other 
self-renewing compartments in vivo. Recent work from our 
lab and collaborators using p16INK4a-deficient and overex-
pressing mice to study self-renewal in three distinct tissues 
(HSCs, neural stem cells [NSCs], and pancreatic islets) has 
suggested that p16INK4a expression is one cause of aging 
in these tissues (Janzen et al., 2006; Krishnamurthy et al., 
2006; Molofsky et al., 2006). These particular self-renew-
ing tissues were chosen for analysis because expression of 
p16INK4a markedly increases in each with aging, and these 
tissues appear to require cdk4 or cdk6 for proliferation. In 
all three cell types, p16INK4a deficiency partially abrogated 
the age-induced decline in proliferation. This decline in 
proliferation was accompanied by functional effects. For 
example, HSCs from old, but not young, p16INK4a-deficient 
animals demonstrated an enhanced ability to serially trans-
plant or competitively repopulate irradiated recipient mice 
compared to wild-type cells from littermate mice. Moreo-
ver, p16INK4a deficiency increased neural progenitor function 
and neurogenesis in old but not young mice. Lastly, older 
p16INK4a-deficient mice demonstrated an age-dependent 
enhancement of islet regeneration after chemical abla-
tion of β cells when compared to littermate wild-type mice. 
Enhanced islet regeneration correlated with resolution of 
diabetes and improved survival. Therefore, these data from 
disparate systems suggest that p16INK4a, in part, promotes 
aging by limiting proliferation and self-renewal. A caveat to 
these results, however, is that they derive from the study 
of mice with a germline deletion of p16INK4a. Therefore, 
some of the age-promoting effects of p16INK4a expression 
observed in these systems may result from mechanisms 
that are not cell autonomous. Future studies in mice using 
tissue-specific inactivation of p16INK4a will address whether 
p16INK4a induces aging in a given tissue in a cell-autono-
mous manner.268 Cell 127, October 20, 2006 ©2006 Elsevier Inc.The effects of p16INK4a loss were remarkably consist-
ent across three self-renewing tissues of vastly differ-
ent biologic properties. Expression of p16INK4a exerted 
age-dependent antiproliferative effects in true stem 
cells (HSCs and NSCs) as well as unipotent progenitors 
(pancreatic β cells). Therefore, p16INK4a appears capa-
ble of promoting aging in disparate tissues that are 
developmentally distinct. Secondly, in no organ stud-
ied (bone marrow, brain, or endocrine pancreas) did 
p16INK4a loss completely abrogate the effects of aging. 
For example, brains from mice lacking p16INK4a still 
demonstrated reduced neurogenesis with aging, and β 
cells from old p16INK4a knockout mice demonstrated less 
regenerative capacity than those of young wild-type 
mice. Therefore, p16INK4a-independent aging occurs 
in these compartments. The molecular basis of this 
p16INK4a-independent aging is unknown, although Arf 
is one obvious candidate as its expression is potently 
antiproliferative and increases in many murine tissues 
with aging to a degree comparable to p16INK4a. Further 
experiments will be required to determine which age-
induced phenotypes involve p16INK4a and Arf and which 
are Ink4a/Arf independent.
The Regulation of INK4a/ARF/INK4b Expression
Given the importance of products of the INK4a/ARF/
INK4b locus in tumor suppression and aging, regulation 
of the locus has been an area of intense study. Evidence 
suggests that INK4a/ARF expression increases at an 
early stage of tumorigenesis (reviewed in Sherr, 2000), 
but the precise stimuli relevant to cancer that induce the 
expression of the locus are unknown. Additionally, the 
molecular characteristics of aging that lead to increased 
p16INK4a expression are similarly unclear. Therefore, 
it has not been possible to determine if the beneficial 
signals that serve to prevent malignancy by inducing 
INK4a/ARF/INK4b early in the life of a would-be cancer 
cell are the same undesirable signals that promote aging 
by inducing p16INK4a. Work in these fields, however, has 
proceeded at a rapid pace, and several recent develop-
ments have enhanced our understanding of the control 
of INK4a/ARF/INK4b expression.
Although some stimuli are known that selectively reg-
ulate p16INK4a but not ARF, or vice versa, the two genes 
are largely coregulated in rodents (Krishnamurthy et al., 
2004; Zindy et al., 1997). That is, increases in p16INK4a in 
response to neoplastic signals or with aging are often 
mirrored by a comparable increase in Arf expression. 
In contrast, coregulation of p16INK4a and ARF in human 
cells is not well established. For example, in cultured 
human cells, senescence generally occurs in the set-
ting of increased expression of p16INK4a, but not ARF, and 
enforced RAS-RAF activation also appears to induce 
only p16INK4a in human cells (Huot et al., 2002; Micha-
loglou et al., 2005; Munro et al., 1999). Likewise, with 
human aging, only an increase in p16INK4a expression has 
been reported (Melk et al., 2004; and our own unpub-
lished observations), although studies of ARF expres-
sion in human aging have not been comprehensive. 
Expression of p15INK4b does not correlate with that of 
p16INK4a and/or Arf across a large panel of normal rodent 
tissues (Krishnamurthy et al., 2004; Zindy et al., 1997), 
but induction and repression of p15INK4b has been noted 
in response to a few signaling events, such as RAS acti-
vation, that also induce INK4a/ARF expression (Figure 2 
and described below).
Numerous noxious stimuli have been reported to 
induce p16INK4a and/or ARF expression in vitro and in 
vivo. In particular, expression of p16INK4a increases after 
several DNA-damaging stimuli including UV light (Pavey 
et al., 1999; Piepkorn, 2000), oxygen radicals (Chen et 
al., 2004; Ito et al., 2004, 2006; Stockl et al., 2006), ion-
izing radiation (Meng et al., 2003; Wang et al., 2006), 
chemotherapeutic agents (Meng et al., 2003; Robles 
and Adami, 1998), and telomere dysfunction (Jacobs 
and de Lange, 2004). It is important to note, however, 
that in most of these systems, detectable induction of 
p16INK4a occurs 2 to 4 weeks after the DNA-damaging 
insult (see for example Jacobs and de Lange, 2004; 
Robles and Adami, 1998; Wang et al., 2006). Moreo-
ver, the induction of p16INK4a in response to these stres-
sors is often associated with MAPK activation (Bulavin 
et al., 2004; Ito et al., 2006; Iwasa et al., 2003). This 
delayed response of p16INK4a compared to the very rapid 
response of p53 to DNA damage may explain the rela-
tionship between p16INK4a and p21CIP, a transcriptional 
target of p53, in serially passaged cultures of human 
fibroblasts undergoing senescence in response to tel-
omere dysfunction. Under these circumstances, peak 
expression of p21CIP precedes that of p16INK4a by a few 
weeks (Stein et al., 1999), and the expression of the 
Figure 2. Regulation of the INK4a/ARF/INK4b Locus 
Positive and negative regulators of p15INK4b, ARF, and p16INK4a expres-
sion. Some proteins specifically influence the expression of a single 
locus member whereas others influence multiple genes. Repressors 
(red) are shown in the upper part of the figure and activators (blue) are 
shown in the lower half.two cell-cycle inhibitors do not colocalize in individual 
cells of such cultures (Herbig et al., 2004). Stimuli that 
induce Arf have been best characterized in murine 
embryo fibroblasts and include oncogene activation as 
well as the act of culture itself. Regulation of p15INK4b in 
response to stressors has not been as thoroughly stud-
ied. Increased expression of p15INK4b is not seen with 
aging (Krishnamurthy et al., 2004; Zindy et al., 1997) 
but has been noted with TGF-β signaling (Reynisdot-
tir et al., 1995) and in some models of RAS-induced 
senescence (Collado et al., 2005) (Figure 2).
As for molecular regulators, several tumor-relevant 
and/or stress signaling pathways are known to influ-
ence expression of the INK4a/ARF/INK4b locus (Figure 
2). Arguably the best studied of these molecular signals 
are those that induce the ERK MAPK pathway through 
activating mutations of RAS and its downstream effec-
tor, B-RAF. A few models have been suggested as to 
how RAS activation might lead to increased Ink4a/Arf 
expression including ERK-mediated activation of Ets1/2 
to induce p16INK4a (Ohtani et al., 2001) and Jun-mediated 
activation of the transcription factor DMP1 to induce 
ARF expression (Sreeramaneni et al., 2005). The func-
tional importance of RAS-RAF signaling to p16INK4a and 
ARF is supported by the frequent finding of homozygous 
INK4a/ARF deletion in melanoma, the majority of which 
harbor mutations of N-RAS or B-RAF.
Additionally, a few repressors of INK4a/ARF/INK4b 
expression have been identified. For example, the T 
box proteins (e.g., Tbx2 [Jacobs et al., 2000]) and the 
polycomb group (PcG) genes (BMI-1, Cbx7, Mel18) 
have been reported to repress all three genes (p16 Ink4a, 
p15Ink4b, and ARF) (Gil et al., 2004; Jacobs et al., 1999). 
Bmi1 deficiency in mice is associated with failure to 
maintain diverse self-renewing stem cells (e.g., HSCs 
and NSCs), which can in large part be rescued by Ink4a/
Arf deficiency (Bruggeman et al., 2005; Jacobs et al., 
1999; Molofsky et al., 2003, 2005; Park et al., 2003). In 
contrast, homeotic transformations of the axial skeleton 
noted in mice lacking Bmi1 are not rescued by loss of 
Ink4a/Arf (Jacobs et al., 1999). The relationship of PcG 
complexes to INK4a/ARF/INK4b expression has been 
particularly provocative as BMI-1 is required for stem 
cell maintenance of HSCs and NSCs, and the ability of 
these complexes to create heritable epigenetic marks 
might suggest a nongenetic mechanism whereby cells 
could carry the memory of prior aging-related expo-
sures. Nonetheless, it has not been possible to show a 
consistent decline in Bmi1 mRNA levels with aging, and 
the precise mechanism whereby BMI-1 represses the 
INK4a/ARF/INK4b locus is unknown.
Oncogenic stress has been associated with Ink4a/
Arf expression, and several molecules (e.g., MYC, ABL, 
AKT) that induce growth and proliferation have been 
reported to regulate one or more products of the INK4a/
ARF/INK4b locus. At least two mechanisms whereby 
such proliferative signals induce INK4a/ARF/INK4b 
expression have been suggested. First, the E2F tran-Cell 127, October 20, 2006 ©2006 Elsevier Inc. 269
scription factors that regulate the expression of numer-
ous genes critical to the cell cycle have been attractive 
candidates in this regard. Both the Arf and p16INK4a pro-
moters harbor putative E2F binding sites, and overex-
pression of E2F1 induces Arf activation (Bates et al., 
1998; DeGregori et al., 1997). In accord with these find-
ings, a recent report has demonstrated in MEFs that 
the binding of E2F3b to the Arf promoter represses Arf, 
whereas the binding of the “proliferative” E2Fs (E2F1 
and E2F3a) enhances Arf expression (Aslanian et al., 
2004). These findings suggest a mechanism by which 
Arf expression is coupled with the cell-cycle machinery 
that regulates S phase entry. A second link between 
cell-cycle control and expression of the INK4a/ARF/
INK4b locus has been suggested by the recent finding 
of a CDC6-mediated coupling between DNA replication 
and INK4a/ARF/INK4b activation (see below). Whether 
these mechanisms function independently or in con-
cert has not been resolved.
Although many genetic alterations and stimuli regulate 
the mRNA expression of the INK4a/ARF/INK4b locus 
(Figure 2), less is known about the posttranslational 
regulation of its protein products. Both p16INK4a and Arf 
have been reported to be polyubiquitinated on nonlysine 
residues in their N termini by yet to be defined E3 ubiq-
uitin ligases (Ben-Saadon et al., 2004; Kuo et al., 2004). 
Ubiquitination of Arf occurs efficiently in cells lacking 
MDM2 and p53, implying that neither is involved in its 
ubiquitination. Further work is required to establish the 
importance of these posttranslational events in tumor 
suppression.
Silencing of the INK4a/ARF/INK4b Locus by Cdc6
A particularly intriguing recent finding with regard to 
INK4a/ARF/INK4b regulation suggests a coordination of 
transcription at the locus and DNA replication. Although 
DNA replication and transcription are generally con-
sidered distinct processes, coupling of the processes 
has been described in yeast. In S. cerevisiae, the tran-
scriptional silencing of mating loci is mediated by the 
binding of a silencer protein complex (SPC) to specific 
DNA origins of replication (Fox and McConnell, 2005). 
Figure 3. CDC6 Repression of the INK4a/ARF/INK4b Locus
Interaction of CDC6 with the origin of replication RDINK/ARF results in the 
recruitment of other members of the pre-replication complex and his-
tone deacetylases, resulting in the heterochromatinization of the p15INK4b, 
ARF, and p16INK4a promoters and silencing of gene expression.270 Cell 127, October 20, 2006 ©2006 Elsevier Inc.However, some of the protein subunits that comprise the 
SPC complex differ from the complex involved in DNA 
replication. Furthermore, some of the dual functions of 
common proteins involved in both DNA replication and 
transcriptional silencing are separable as shown by 
studies of spontaneous revertants and complementation 
studies in yeast (Fox and McConnell, 2005). Therefore, 
the processes of DNA replication and mating loci silenc-
ing partially, but not completely, overlap in yeast. Such 
coupling of DNA replication and transcriptional silencing 
has not been previously described in vertebrates.
Gonzalez and colleagues have now reported a simi-
lar coordination between silencing of the INK4a/ARF/
INKb locus and DNA replication. The authors identified 
a DNA replication origin (RDInk/ARF) in close proximity to 
the INK4a/ARF/INK4b locus that appears to transcrip-
tionally repress p15INK4b, p16INK4a, and ARF expression in 
a manner dependent on CDC6 (Gonzalez et al., 2006) 
(Figure 3). In DNA replication, CDC6 interacts with the 
origin recognition complex and recruits factors that 
unwind the DNA helix. The authors first showed that 
heterochromatinization of RDInk/ARF induced by RNA 
interference (RNAi) against complementary genomic 
DNA in cells (Kawasaki and Taira, 2004; Morris et al., 
2004) led to transcriptional repression of the INK4a/
ARF/INKb locus. In addition, they showed that CDC6, 
along with other members of the pre-recognition com-
plex, specifically bound to RDInk/ARF. Finally, the authors 
found that ectopic expression of cdc6 was associated 
with reduced expression of p15INK4b, Arf, and p16INK4a and 
the recruitment of histone deacetylases to the RDInk/ARF 
as well as to the promoters of p16INK4a and Arf. There-
fore the authors hypothesized that cdc6 expression 
might regulate both DNA replication and transcription at 
RDInk/ARF. The authors provided further functional data of 
this silencing: Expression of cdc6 in MEFs significantly 
increased foci formation and enhanced transformation 
by oncogenic RAS. Importantly, neither short-hairpin 
RNA (shRNA) to RDInk/ARF nor cdc6 overexpression had 
noticeable effects on the transformation of MEFs lack-
ing Ink4a/Arf, suggesting that the oncogenic effects of 
cdc6 are mediated specifically through repression of the 
Ink4a/Arf/Inkb locus. Lastly, in an immunohistochemi-
cal analysis of human non-small cell lung cancers, there 
was an inverse correlation between CDC6 and p16INK4a 
protein expression, a result consistent with the model 
that CDC6 functions as an oncogene in human lung 
cancer by repressing p16INK4a. In aggregate, these find-
ings suggest a novel molecular connection between 
DNA replication and INK4a/ARF/INK4b transcription. It 
remains to be seen how this mechanism of regulation 
interacts with other known repressors or activators of 
INK4a/ARF/INK4b expression.
The Functions of the INK4a/ARF/INK4b Proteins
Although we believe that the principal biochemi-
cal activities of the INK4 proteins and ARF are well 
understood, how these proteins prevent cancer and 
promote physiologic aging is a matter of debate. 
A leading candidate in this regard, however, is the 
induction of senescence, a specialized form of growth 
arrest. Senescence is distinguished from other forms 
of growth arrest in that it is generally permanent and 
is associated with characteristic morphologic altera-
tions, enzymatic activities (SA-β-galactosidase), and 
novel changes in chromatin architecture (SA-hetero-
chromatic foci) (reviewed in Campisi, 2005). Although, 
as stated, the relative senescence-promoting activ-
ity of p16INK4a and ARF may differ in humans versus 
mice or by cell type, the activation of the INK4a/ARF 
locus is intimately associated with the induction of 
senescence in most systems. The increase in p16INK4a 
and/or ARF expression in cells harboring oncogenic 
lesions such as ABL, MYC, or RAS activation is 
thought to constitute an important barrier to cancer 
and has been termed oncogene-induced senescence 
(Serrano et al., 1997). Oncogene-induced senes-
cence has recently been described in vivo in preneo-
plastic tissues of both the mouse and human (Braig 
et al., 2005; Chen et al., 2005; Collado et al., 2005; 
Gray-Schopfer et al., 2006; Michaloglou et al., 2005). 
This collection of papers convincingly demonstrates 
an oncogene-induced growth arrest in vivo (with 
the characteristics of senescence) in lymphocytes, 
melanocytes, and epithelia of the lung and prostate. 
The expression of senescence markers in human 
nevi (cutaneous moles) is particularly provocative 
as it suggests that these extremely common cutane-
ous lesions would become melanomas if not for the 
activation of the senescence machinery. This finding 
indicates that the INK4a/ARF locus exerts a constant 
protective effect even in young humans.
A weakness of the senescence hypothesis has been 
a lack of understanding as to how a cell would discern 
cues for normal physiologic growth from signals for 
oncogenic proliferation. The work of Satyanarayana 
and colleagues (Satyanarayana et al., 2004) provides 
a clue as to how this might occur. In this work, the 
authors demonstrated that the induction of senes-
cence by classical stimuli required concomitant ERK 
stimulation to efficiently induce senescence. This 
observation suggests that senescence requires in 
essence two things: signaling induced by a strong cel-
lular stress (such as telomere dysfunction or oxygen 
radicals) and some coincident period of signaling to 
promote proliferation (such as ERK activation). This 
combination appears key to the induction of INK4a/
ARF expression and senescence. Additionally, the 
induction of senescence appears to be a relatively 
slow process compared to the onset of growth arrest. 
For example, using a cell line in which p16INK4a expres-
sion can be controlled, Dai and Enders have shown 
that p16INK4a expression causes growth arrest within 
24 hr of induction but does not cause senescence 
unless expression of p16INK4a is maintained for 6 days 
(Dai and Enders, 2000). Therefore, senescence can be considered a response of cellular desperation after 
a prolonged period of mixed signals including signals 
for both stress and growth.
Importantly, however, p16INK4a, Arf, and p15INK4b need 
not induce senescence to prevent cancer or contrib-
ute to aging. For example, increased p16INK4a expres-
sion in stem cell compartments with aging may merely 
attenuate self-renewal by decreasing the frequency of 
cell-cycle entry, in the absence of permanent growth 
arrest. Along the lines of this model, a novel antican-
cer function for p16INK4a has been recently suggested 
by McDermott and colleagues (McDermott et al., 
2006). Using cultures of primary human mammary 
epithelial cells (HMECs), the authors show that p16INK4a 
inactivation results in centrosome duplication lead-
ing to genomic instability. The investigators showed 
that knockdown of p16INK4a in HMECs treated with the 
reversible S phase cell-cycle inhibitor hydroxyurea 
(HU) results in an increase in supernumerary cen-
trosomes and genomic abnormalities at metaphase. 
Likewise, re-expression of p16INK4a in HU-treated 
HMECs lacking p16INK4a abrogated the formation of 
cells with supernumerary centrosomes. Therefore, 
this work suggests an additional mechanism whereby 
p16INK4a expression could decrease transformation in 
proliferating, and therefore nonsenescent, cells.
Future Questions
We believe the tools of mouse genetics have more to 
teach us about the Ink4a/Arf/Ink4b locus. For exam-
ple, it will be important to determine the phenotypes 
of p15INK4b/p16INK4a, p15INK4b/Arf, and Ink4a/Arf/Ink4b 
compound knockout mice to understand if there is 
cooperation in tumor suppression between p15INK4b 
and the products of the Ink4a/Arf locus. Undoubtedly, 
high-resolution tumor genotyping in an unbiased and 
genome-wide manner will supplement murine genetic 
studies to refine our understanding of the tumor sup-
pressor roles of the various products of the INK4a/
ARF/INK4b locus in human cancers. Moreover, the 
majority of knockout experiments performed to date 
have utilized mice with germline deficiencies of the 
products of the Ink4a/Arf/Ink4b locus. A limitation of 
this approach, however, is the possibility of develop-
mental compensation, particularly with regard to the 
many known regulators of the cell cycle. For exam-
ple, compensation among the RB family members is 
well described (Sage et al., 2000), and in particular, 
we have noted pronounced alterations in the expres-
sion of p15INK4b and p16INK4a in INK4-deficient MEFs 
(M. Ramsey and N.E.S., unpublished data). There-
fore, it will be important to ascertain if tissue-specific, 
somatic deletion of the Ink4a/Arf/Ink4b products is 
more oncogenic than germline deficiencies.
Understanding how p16INK4a promotes aging, whether 
by inducing senescence or decreasing the frequency of 
cell-cycle entry, is an important issue. The data dem-
onstrating an increase in p16INK4a expression with aging Cell 127, October 20, 2006 ©2006 Elsevier Inc. 271
can be reconciled with two different models (Figure 4). 
With aging, stochastic activation of p16INK4a expression 
could occur on a cell-by-cell basis in self-renewing com-
partments to induce senescence (Figure 4A), or expres-
sion could increase simultaneously within the majority of 
cells of a self-renewing compartment (Figure 4B). In the 
latter model, self-renewal would be impaired by p16INK4a 
expression by decreased frequency of cell-cycle entry in 
the absence of senescence. The finding that with aging, 
there is a correlation between an increased expression of 
p16INK4a and the expression of cellular markers of senes-
cence in primate skin (Herbig et al., 2006), human vas-
culature (Matthews et al., 2006), and rodent and human 
kidney (Krishnamurthy et al., 2004; Melk et al., 2003, 
2004) supports the senescence model (Figure 4A); but 
such correlative observations do not establish a causal 
role for senescence in aging. Addressing this ques-
tion has important implications for future “anti-aging” 
therapies—that is, can cellular aging be reversed? The 
model in which cell-cycle entry is decreased (Figure 4B) 
suggests that the age-induced defects in proliferation 
could be ameliorated merely by reducing p16INK4a levels 
or otherwise increasing CDK4/6 activity in these cells. 
The senescence model (Figure 4A), however, suggests 
that the defects in self-renewal could only be remedied 
through more drastic measures, for example replace-
ment with young, self-renewing cells from an exogenous 
source.
Lastly, a better and integrated understanding of 
the in vivo regulation of the INK4a/ARF/INK4b locus 
with cancer and aging is needed. The suggestion by 
Gonzalez and colleagues that overexpression of CDC6 
Figure 4. models of p16INK4a Function in Cellular Aging
Tissue-specific, self-renewing cells undergo repeated divisions, and 
p16INK4a expression increases with age as a consequence of undefined 
stimuli. 
(A) Senescence model: p16INK4a expression occurs stochastically in a 
subpopulation of cells resulting in their senescence. In this model, the 
capacity for self-renewal of the nonsenescent cells is not affected. 
(B) The decreased cell-cycle entry model: expression of p16INK4a in-
creases uniformly in the tissue-specific, self-renewing cells resulting 
in a decrease in the self-renewal capacity of the entire compartment. 
In either scenario, the overall regenerative capacity of the self-renew-
ing cell compartment is compromised over time. Self-renewal is indi-
cated by curved arrows, senescent cells are colored blue.272 Cell 127, October 20, 2006 ©2006 Elsevier Inc.can transcriptionally silence the INK4a/ARF/INK4b 
locus through a nearby ORI is highly novel, describing 
a form of transcriptional repression without precedent 
in vertebrate biology. It is now important to reconcile 
this finding with the extensive list of transcription fac-
tors and other effectors (Figure 2) known to modulate 
INK4a/ARF/INK4b expression. For example, CDC6-
mediated heterochromatinization might play some 
role in the other two incompletely understood forms of 
INK4/ARF repression: that induced by overexpression 
of PcG or DNA methylation.
In summary, the role of INK4a/ARF/INK4b products 
in tumor suppression is well established, and new data 
similarly suggest an important role for p16INK4a at least 
in mammalian aging. Additional recent data suggest 
that tumor suppression by INK4a/ARF results from the 
in vivo induction of senescence, although senescence-
independent anticancer functions such as a role for 
p16INK4a in regulating tumor ploidy have also been sug-
gested. Given these critical physiological roles, under-
standing the regulation of this locus has assumed new 
importance. Several provocative questions remain 
including the relationship of a recently identified cou-
pling of DNA replication and INK4a/ARF/INK4b silenc-
ing with other known regulatory events that influence the 
locus. A holistic understanding of these many factors 
that communicate with the INK4a/ARF/INK4b locus will 
allow precise determination of how cells sense the earli-
est effects of carcinogenesis, as well as further delineate 
the stimuli that tell cells that they are growing old.
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